Such measures include investigations to identify the aetiology of kidney disease and controlling cause-specific risk-factors [30], such as diabetes [31], or prescribing nephroprotective medications, including renin–angiotensin system inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, or glucagon-like peptide-1 (GLP1) receptor agonists [32–35]. Here, SLC5A2 is linked to kidney disorder.